NEW YORK, Nov. 12, 2021 /CNW/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the
"Company"), a leading biotech company developing
psychedelic-inspired therapies, is pleased to announce that its
CEO, Robert Barrow, will be speaking
at Jefferies 2021 London Healthcare Conference, taking place on
November 16-19. Management will be
available during the conference for in-person and virtual
one-on-one meetings.
A video webcast of the presentation will be available for
viewing on-demand beginning on Wednesday,
November 17 at 9:20 AM GMT for
those registered for the event. The webcast will also be accessible
in the "Investors" section of MindMed's website. MindMed will
maintain an archived replay of the webcast on its website for 30
days after the conference.
About MindMed
MindMed is a clinical-stage psychedelic medicine biotech company
that seeks to discover, develop and deploy psychedelic-inspired
medicines and therapies to address addiction and mental illness.
The Company is assembling a compelling drug development pipeline of
innovative treatments based on psychedelic substances including
psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The
MindMed executive team brings extensive biopharmaceutical
experience to MindMed's approach to developing the next generation
of psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
Media Contact: mindmed@150bond.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-to-present-at-the-jefferies-london-healthcare-conference-301422852.html
SOURCE Mind Medicine (MindMed) Inc.